SCHEMBL4466090

SCHEMBL4466090

COc1ccc2c(=O)n(-c3ccc(OCCCN4CCCCC4)cc3)c(C)nc2c1

nearest known ligand 0.98

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 20/20 0.98
KCNH2 Q12809 16/20 0.98
ADRA1A P35348 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485049 0.99 HRH3 (1.00) HRH3KCNH2ADRA1A
SCHEMBL4468342 0.92 HRH3 (0.98) HRH3KCNH2ADRA1A
SCHEMBL502103 0.92 HRH3 (0.98) HRH3KCNH2ADRA1A
SCHEMBL4473018 0.91 HRH3 (1.00) HRH3KCNH2ADRA1A
SCHEMBL22067586 0.90 HRH3 (0.84) HRH3KCNH2ADRA1A
SCHEMBL4467566 0.89 HRH3 (0.79) HRH3KCNH2ADRA1A
SCHEMBL4474782 0.89 HRH3 (0.80) HRH3KCNH2ADRA1A
SCHEMBL4466551 0.89 HRH3 (0.98) HRH3KCNH2ADRA1A
SCHEMBL4461677 0.89 HRH3 (0.98) HRH3KCNH2ADRA1A
SCHEMBL4459167 0.89 HRH3 (0.80) HRH3KCNH2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 HRH3 3/4885KCNH2 299/4885ADRA1A 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.